Antiangiogenic strategies, compounds, and early clinical results in breast cancer
Open Access
- 29 February 2004
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 49 (2), 91-107
- https://doi.org/10.1016/s1040-8428(03)00168-9
Abstract
No abstract availableKeywords
This publication has 112 references indexed in Scilit:
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Metronomic scheduling: the future of chemotherapy?The Lancet Oncology, 2001
- The Hallmarks of CancerCell, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Crystal structure of the angiogenesis inhibitor endostatin at 1.5AresolutionThe EMBO Journal, 1998
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences of the United States of America, 1994
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971
- ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESISThe Journal of Experimental Medicine, 1971